Company registration number SC460140 (Scotland)
PENNYBURN PHARMACY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
PENNYBURN PHARMACY LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 9
PENNYBURN PHARMACY LTD
BALANCE SHEET
AS AT
30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
554,821
602,857
Tangible assets
5
83,029
90,642
637,850
693,499
Current assets
Stocks
92,935
66,933
Debtors
6
363,791
328,811
Cash at bank and in hand
61,824
222,684
518,550
618,428
Creditors: amounts falling due within one year
7
(443,514)
(488,552)
Net current assets
75,036
129,876
Total assets less current liabilities
712,886
823,375
Creditors: amounts falling due after more than one year
8
(671,350)
(763,195)
Provisions for liabilities
(17,820)
(19,669)
Net assets
23,716
40,511
Capital and reserves
Called up share capital
500
500
Profit and loss reserves
23,216
40,011
Total equity
23,716
40,511

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

PENNYBURN PHARMACY LTD
BALANCE SHEET (CONTINUED)
AS AT
30 NOVEMBER 2025
30 November 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 17 April 2026 and are signed on its behalf by:
Mr D Stribling
Director
Company Registration No. SC460140
PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
1
Accounting policies
Company information

Pennyburn Pharmacy Ltd is a private company limited by shares incorporated in Scotland. The registered office is Pleasantfield Farm, By Alloway, Ayr, United Kingdom, KA6 6BU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.4
Intangible fixed assets - goodwill

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

 

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
- 15% on cost
Fixtures and fittings
- 15% on cost
Motor vehicles
- 20% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 7 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
21
20
4
Intangible fixed assets
Goodwill
£
Cost or valuation
At 1 December 2024 and 30 November 2025
1,344,999
Amortisation and impairment
At 1 December 2024
742,142
Amortisation charged for the year
48,036
At 30 November 2025
790,178
Carrying amount
At 30 November 2025
554,821
At 30 November 2024
602,857

If revalued assets were stated on an historical cost basis rather than a fair value basis, the total amounts included would have been as follows:

2025
2024
£
£
Cost
1,100,000
1,100,000
Accumulated amortisation
-
-
Carrying value
1,100,000
1,100,000
PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 8 -
5
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 December 2024
195,472
184,385
15,500
395,357
Additions
-
0
5,808
5,695
11,503
Disposals
-
0
-
0
(7,500)
(7,500)
At 30 November 2025
195,472
190,193
13,695
399,360
Depreciation and impairment
At 1 December 2024
132,004
157,612
15,099
304,715
Depreciation charged in the year
11,098
6,680
1,337
19,115
Eliminated in respect of disposals
-
0
-
0
(7,499)
(7,499)
At 30 November 2025
143,102
164,292
8,937
316,331
Carrying amount
At 30 November 2025
52,370
25,901
4,758
83,029
At 30 November 2024
63,468
26,773
401
90,642

The net book value of tangible fixed assets includes £51,810 (2024 - £62,753) in respect of assets held under hire purchase contracts.

6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
303,723
248,912
Other debtors
37,731
61,577
Prepayments and accrued income
22,337
18,322
363,791
328,811
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
42,066
42,066
Obligations under finance leases
20,257
20,257
Trade creditors
268,723
313,703
Corporation tax
43,401
53,626
Other taxation and social security
14,868
8,068
Other creditors
44,815
42,492
Accruals and deferred income
9,384
8,340
443,514
488,552
PENNYBURN PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 9 -
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
651,932
723,521
Obligations under finance leases
19,418
39,674
671,350
763,195
9
Secured debts

The following secured debts are included within creditors:

 

Bank loans: £693,997 (2024: £765,587)

Hire purchase contracts: £39,674 (2024: £59,931)

 

The bank loan is secured by a bond and floating charge over the assets of the company in addition to personal guarantees by the directors amounting to £100,000.

 

Hire purchase creditors are secured over the asset to which they relate.

 

10
Directors' advances, credits and guarantees

An interest free loan existed between the directors and the company. The balance due to the directors at 30 November 2025 was £395 (2024: £425).

11
Ultimate controlling party

The company is jointly controlled by the two shareholders, Mr D Stribling and Mrs F Stribling. As the issued share capital of the company ranks pari passu, neither can in isolation exercise complete control over the company.

2025-11-302024-12-01falsefalsefalse17 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr D StriblingMrs F I StriblingSC4601402024-12-012025-11-30SC4601402025-11-30SC4601402024-11-30SC460140core:Goodwill2025-11-30SC460140core:Goodwill2024-11-30SC460140core:PlantMachinery2025-11-30SC460140core:FurnitureFittings2025-11-30SC460140core:MotorVehicles2025-11-30SC460140core:PlantMachinery2024-11-30SC460140core:FurnitureFittings2024-11-30SC460140core:MotorVehicles2024-11-30SC460140core:CurrentFinancialInstrumentscore:WithinOneYear2025-11-30SC460140core:CurrentFinancialInstrumentscore:WithinOneYear2024-11-30SC460140core:Non-currentFinancialInstrumentscore:AfterOneYear2025-11-30SC460140core:Non-currentFinancialInstrumentscore:AfterOneYear2024-11-30SC460140core:Non-currentFinancialInstruments2025-11-30SC460140core:Non-currentFinancialInstruments2024-11-30SC460140core:ShareCapital2025-11-30SC460140core:ShareCapital2024-11-30SC460140core:RetainedEarningsAccumulatedLosses2025-11-30SC460140core:RetainedEarningsAccumulatedLosses2024-11-30SC460140bus:Director12024-12-012025-11-30SC460140core:Goodwill2024-12-012025-11-30SC460140core:PlantMachinery2024-12-012025-11-30SC460140core:FurnitureFittings2024-12-012025-11-30SC460140core:MotorVehicles2024-12-012025-11-30SC4601402023-12-012024-11-30SC460140core:Goodwill2024-11-30SC460140core:PlantMachinery2024-11-30SC460140core:FurnitureFittings2024-11-30SC460140core:MotorVehicles2024-11-30SC4601402024-11-30SC460140core:CurrentFinancialInstruments2025-11-30SC460140core:CurrentFinancialInstruments2024-11-30SC460140bus:PrivateLimitedCompanyLtd2024-12-012025-11-30SC460140bus:SmallCompaniesRegimeForAccounts2024-12-012025-11-30SC460140bus:FRS1022024-12-012025-11-30SC460140bus:AuditExemptWithAccountantsReport2024-12-012025-11-30SC460140bus:Director22024-12-012025-11-30SC460140bus:FullAccounts2024-12-012025-11-30xbrli:purexbrli:sharesiso4217:GBP